Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial - Wikidata - thesis-toulmin - TriplyDB

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

http://www.wikidata.org/entity/Q28304712

about

The Prevalence and Management of Systemic Amyloidosis in Western Countries Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis Infiltrative Cardiomyopathies Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs X-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitors Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR)First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy Evolving landscape in the management of transthyretin amyloidosis The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response Modifications of the 7-Hydroxyl Group of the Transthyretin Ligand Luteolin Provide Mechanistic Insights into Its Binding Properties and High Plasma Specificity Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer Transthyretin Cardiac Amyloidosis in Older Americans.Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis.Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel.Proficiency of nerve conduction using standard methods and reference values (Cl. NPhys Trial 4)Novel drugs targeting transthyretin amyloidosis.Recent progress in the understanding and treatment of transthyretin amyloidosis.Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy.An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.Recent advances in transthyretin amyloidosis therapy Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.Cooperative stabilization of transthyretin by clusterin and diflunisal.Modulating inhibitors of transthyretin fibrillogenesis via sulfation: polychlorinated biphenyl sulfates as models.In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis Early detection of nerve injury in transthyretin-related familial amyloid polyneuropathy.Outcome of gastric emptying and gastrointestinal symptoms after liver transplantation for hereditary transthyretin amyloidosis.A fluorogenic aryl fluorosulfate for intraorganellar transthyretin imaging in living cells and in Caenorhabditis elegans.The Temporal Profiles of Changes in Nerve Excitability Indices in Familial Amyloid Polyneuropathy.Transthyretin deposition in articular cartilage: a novel mechanism in the pathogenesis of osteoarthritis.Enhancing bottom-up and top-down proteomic measurements with ion mobility separations Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study Protein post-translational modifications and misfolding: new concepts in heart failure.The pathological and biochemical identification of possible seed-lesions of transmitted transthyretin amyloidosis after domino liver transplantation.A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis.Targeting protein aggregation for the treatment of degenerative diseases A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis.Cardiac amyloidosis presenting as recurrent acute coronary syndrome with unobstructed coronary arteries: Case report.

P2860

Q26740436-22A70F9E-CAC7-4BB1-8617-95359C587C55 Q26782089-87462242-9E52-4D7A-9DD8-DF91A3B35820 Q26798533-424EFE06-F7D4-4165-A717-1CB086E92D8A Q27009309-123B5914-3E8E-4008-B302-AF802A52C809 Q27701718-21B911E2-D0B3-4A5C-8A4C-DF00F2D0B955 Q27704552-2FEE27D3-99DF-4579-84CA-AF2CD746752B Q28071522-92563AC9-AA8E-48C1-A574-79790E5D91D9 Q28086773-30B77683-012A-47A2-8FD3-E04863F6905E Q28547541-237D0D03-E7B6-420F-883F-F8532FAA7412 Q28551199-D810C353-C748-450A-A5B5-81C71855B2BF Q28551432-98ED41D3-BE3E-4A99-A433-E510237AC565 Q30244227-4D16912F-9A56-4B3E-AD6D-0C1E646998F3 Q33423160-E3BBA39B-F99E-43D7-84B4-2848B89D9916 Q33671132-59CD7BB9-4E59-4D6F-91CD-2FFFB501702E Q34214542-53076337-9539-415A-A5E3-73F00EF0C431 Q34400138-F5F37C3F-161B-4F40-BB1B-2B842DE83932 Q34416193-30E7C9F4-1BA9-45B8-9CB8-E4B82EA26416 Q34422510-8D7B14AC-5949-40CC-BA4A-D28150277FE3 Q34428314-1B46A0BE-7B51-4ACB-80B1-6304F2BC4745 Q34664696-B12791F3-695D-4CE1-BA55-055BFC99F87F Q34838524-FE23D91E-2FD1-4F38-AEA2-57C3FB1503FD Q35001154-D976302C-A32F-4216-930E-279BD610EDD4 Q35082885-E94328E3-CED6-458B-848D-FF6324CF6C74 Q35119383-637144EA-2235-4356-AB95-7A1B950A2BBA Q35244195-CDDACEA3-F65D-46B4-AF61-53275A9E0941 Q35533969-A7367B39-269F-4AC1-875F-D0A6D6924C14 Q35556198-5EB77712-527F-4764-85CD-2AE16F8513E4 Q35756357-D80F013E-1541-4A87-BC57-349E74F61D51 Q35830457-814C464D-089D-406A-84F7-1165E409FBE7 Q35901035-B87E137A-18D3-46A8-9245-3B26250AD15D Q35945797-766B1546-3B7B-4F20-9265-08E9AF4104B8 Q35995472-FE706667-F2B6-4E72-9D9B-DA37143F6C55 Q36005668-9C5B782A-BC6F-4C1F-9120-58F4B7286B0E Q36025267-E54E5403-FE76-4E4E-9DD2-CFACE02AE20A Q36028759-78636D17-A000-4B08-97C5-B34884BA2594 Q36097190-0228ABEC-7005-4F70-BF6E-2BD07DEE43D1 Q36159473-051364B5-74B7-4E94-9BCE-C43E2FC7EC01 Q36235980-0C23EAF6-3FE1-4B16-8D44-0B7653D73342 Q36389712-1476366A-A6FB-4D6D-B444-E0198D9AC9E3 Q36426658-9CBCDB22-2D1E-4619-91F6-9A3FAA30B72D

P2860

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

http://www.wikidata.org/entity/Q28304712

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

@ast

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

@en

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

@nl

type

label

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

@ast

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

@en

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

@nl

prefLabel

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

@ast

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

@en

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

@nl

P1433

Q28304712-FAFE5F41-5C06-4820-9699-D0E63E4F414A

P1476

Q28304712-B9E186F1-862B-483D-AC5C-121EEDDE378D

P2093

Q28304712-0B963A09-34C5-4921-8D60-395827111AB3

Q28304712-157E9875-3A6B-40CA-A0E2-C9C393D4B102

Q28304712-28867271-4216-4253-8CE6-1179539F1102

Q28304712-2C3A81C9-CF65-49D5-9B96-6CF91DB103DB

Q28304712-4F261B31-196D-4B7D-8659-26A8C201F51C

Q28304712-5DC82674-059F-4411-B6A3-1D7127F43947

Q28304712-656E0509-4238-4A35-9C7D-F2DB4951E7C1

Q28304712-6944D5EB-342C-4C4C-B39C-57E4FCAF8422

Q28304712-78055D5D-8D7F-4748-82C3-43CBA01B81F9

Q28304712-7C6AC479-642B-4A75-B1B6-87BDB6069BAC

P2860

Q28304712-10706E39-BDA2-4E45-801C-D3F017AC108E

Q28304712-11F0A713-8664-4769-8FE8-B9F4F4BF7A34

Q28304712-1813231E-E3E8-40A1-AEF0-96FD77471633

Q28304712-1F22FAD3-C374-4892-B232-0EB48A4D05C8

Q28304712-23897DE4-DEC0-4480-92FE-A681AAFE8144

Q28304712-253A21F9-5C41-45E3-A95E-9E51568D9278

Q28304712-5C21DC90-5848-4237-821A-24EA6260EDCA

Q28304712-6E276D68-145D-40C9-9D88-18969625E197

Q28304712-71EF8B66-8289-43D0-A0A8-1FB93B0B7D3A

Q28304712-74F9DA2A-4983-468C-A701-9636AE805610

P304

Q28304712-FA27DF0E-2B0B-4933-962D-C060B249CCE2

P31

Q28304712-A722A8E0-8EB3-4C9E-BD0A-A1925162921B

P3181

Q28304712-4938BEC5-5BC5-4E0E-9910-320E3F9F8EBA

P356

Q28304712-170824A2-76E1-4E8E-986E-41EA754B04C6

P407

Q28304712-FC5B2680-8FC2-465F-B043-290CED8BD856

P433

Q28304712-8C2DA963-5A69-47EE-A845-0ED8B34342BA

P478

Q28304712-4D487907-C282-4878-BAF3-444AE2981BC9

P50

Q28304712-343B049F-E45E-428E-BFCE-D30B5C632BC5

Q28304712-36720B62-7270-476D-92B5-184A2D79122E

Q28304712-7F787AB9-9175-4B81-960F-9A8ACBB3A0AA

Q28304712-85615378-35C5-4757-B75F-EFA8A1A9F759

Q28304712-CEF38A9E-BA5A-480E-9B91-4BE256F8BCDE

Q28304712-F683D399-A584-4FA6-9125-00198FF7CD4F

P577

Q28304712-37A15B62-B22B-4AD9-BF01-F2BD8C588D5A

P5875

Q28304712-A8516D42-3537-4030-BA07-7CF9177FB894

P698

Q28304712-E094945F-7A9F-446C-8E8F-A4A3E4C3C873

P932

Q28304712-1949A41B-37EA-497C-828F-C3FD3C182713

P3181

P356

JAMA.2013.283815

P1433

Journal of the American Medical Association

P1476

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

@en

P2093

Alice B Bisbee

http://www.w3.org/2001/XMLSchema#string

Andrea Cortese

http://www.w3.org/2001/XMLSchema#string

David C Seldin

http://www.w3.org/2001/XMLSchema#string

Erik Nordh

http://www.w3.org/2001/XMLSchema#string

Janice F Wiesman

http://www.w3.org/2001/XMLSchema#string

Jeffery W Kelly

http://www.w3.org/2001/XMLSchema#string

Jessica Robinson-Papp

http://www.w3.org/2001/XMLSchema#string

John L Berk

http://www.w3.org/2001/XMLSchema#string

Manuel Corato

http://www.w3.org/2001/XMLSchema#string

Martha Skinner

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A

Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein

A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

Trans-suppression of misfolding in an amyloid disease.

Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

The pathway by which the tetrameric protein transthyretin dissociates.

Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.

P304

2658-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2230471

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/JAMA.2013.283815

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

310

http://www.w3.org/2001/XMLSchema#string

P50

Giampaolo Merlini

Alessandro Lozza

Steven R Zeldenrust

P577

2013-12-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259461443

http://www.w3.org/2001/XMLSchema#string

P698

24368466

http://www.w3.org/2001/XMLSchema#string

P932

4139164

http://www.w3.org/2001/XMLSchema#string